Hypovitaminosis D and "Metabolic" Inflammatory Status in Patients With Obesity

Summary

Since obesity is related to systemic chronic inflammatory status and hypovitaminosis D, the study aimed to assess the incidence of hypovitaminosis D in obese patients and the correlations between vitamin D levels, inflammation indices, and bioimpedance measures.

A retrospective study was conducted on a cohort of obese patients. The inflammation-based prognostic scores, diagnosis of liver fibrosis, systemic inflammatory indices, and bioimpedance measures were analyzed. The linear relationship between vitamin D levels and continuous variables was assessed through the Spearman correlation coefficient, and to determine significant predictors of vitamin D levels a stepwise multiple linear regression was used.

Conditions

• Hypovitaminosis D
• Obesity

Interventions

DIAGNOSTIC_TEST

Vitamin D Plasma Level

Blood test measured in ng/ml

DIAGNOSTIC_TEST

Bioelectrical Impedance Analysis (BIA) technique

Measurements of body composition were conducted with Bioelectrical Impedance Analysis (BIA) technique, asking the participants to stand on the device barefoot to complete the analysis. Among all parameters, BMI, phase angle (PhA), total body water (TBW), extracellular (ECW) and intracellular water (ICW), body fat index, and fat and muscular mass were recorded.

DIAGNOSTIC_TEST

Ferritin

Ferritin plasma levels were measured in μg/L

DIAGNOSTIC_TEST

C reactive protein (CRP)

CRP plasma levels were measured in mg/L

DIAGNOSTIC_TEST

Inflammation-based prognostic scores

Glasgow Prognostic Score/modified Glasgow Prognostic Score (GPS/mGPS), Prognostic Nutritional Index (PNI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte ratio (PLR), Lymphocyte-to-monocyte ratio (LMR), Systemic immune-inflammation index (SII) were calculated using blood test results

OTHER

Liver biopsy

A liver biopsy was used to study nonalcoholic steatohepatitis (NASH) and fibrosis according to the Kleiner-Brunt classification

Sponsors & Collaborators

• University of Trieste

  lead OTHER

Principal Investigators

• Silvia Palmisano, MD · University of Trieste

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-01-01

Primary Completion

2021-06-30

Completion

2021-06-30

Countries

• Italy

Study Locations